Thu, Aug. 4, 9:16 AM
- Gainers: CBMX +31%. OCUL +27%. ALIM +18%. GV +18%. SQ +17%. DRAM +16%. XPO +14%. PCRX +12%. FHCO +11%. EPE +10%. EXEL +8%. APHB +7%. SSYS +7%. GOGO +6%. EVOK +5%. TSEM +5%.
- Losers: SGMO -25%. TDOC -21%. INOV -17%. KOOL -13%. SEAS -10%. QUIK -9%. IMGN -9%. CF -8%. AMRN -8%. TRIP -8%. CRC -6%. USCR -6%.
Tue, Jun. 14, 12:51 PM
Tue, Jun. 14, 11:00 AM
Mon, Jun. 13, 4:27 PM
- ImmunoGen (NASDAQ:IMGN) announces plans for a $100M private offering of convertible senior notes due 2021. Price, yield and terms have yet to be announced.
- Net proceeds will fund operations, R&D, capex, working capital and general corporate purposes.
- Shares are off 14% after hours on increased volume.
- Update: On June 15, the company announced that the 4.50% convertible senior notes due 2021 would be priced at par. Initial purchasers have a 30-day option to buy an additional $15M aggregate principal amount of the notes. The conversion rate, which could be adjusted at a later point in time, is 238.7775 shares per $1,000 principal amount (~$4.19 per share).
- Net proceeds should be $96.7M ($111.2M if initial purchasers fully exercise their option to buy more notes).
Fri, Apr. 29, 9:12 AM
- Gainers: PRGN +75%. GNW +16%. P +13%. AMZN +12%. SDRL +11%. EXPE +11%. MNST +11%. ROVI +10%. SNMX +9%. LNKD +7%. CRC +7%. DNR+7%. DRYS +7%. TIVO +6%. LGCY +6%. SHPG +5%. GPL +5%.
- Losers: BIOC -22%. GLNG -17%. EPAY -17%. MOH -15%. SRCL -15%. IMGN -14%. SYNA -11%. AKS -8%. HCLP -8%. ALR -6%. GILD -6%. RXDX -6%.
Thu, Feb. 4, 11:01 AM
- ImmunoGen (IMGN +9.7%) establishes a clinical research collaboration with Merck (MRK -1.4%) to evaluate the combination of IMGN's mirvetuximab soravtansine and Keytruda (pembrolizumab) for the treatment of patients with folate receptor (FR) alpha-positive ovarian cancer. The combination therapy will be added to IMGN's Phase 1b/2 clinical trial called FORWARD II. The agreement, through a Merck subsidiary, includes an option to expand the collaboration to include a Phase 3 study if the results are positive.
- Mirventuximab soravtansine is an antibody-drug conjugate (ADC) that contains a monoclonal antibody (mirventuximab) that binds to FRalpha-positive tumor cells thereby delivering its cytotoxic payload, soravtansine or DM4.
- KEYTRUDA helps the immune system fight tumor cells by blocking the interaction between PD-1, a cell surface receptor expressed on T cells and pro-B cells, and its ligands PD-L1 and PD-L2. PD-1 is an immune checkpoint which down regulates the immune system. Blocking its action activates the immune system to attack cancer cells.
Dec. 18, 2015, 5:41 PM
Sep. 18, 2015, 12:45 PM
Jul. 13, 2015, 5:35 PM
Jun. 2, 2015, 12:45 PM
Jun. 1, 2015, 9:48 AM
- ImmunoGen (IMGN +49%) jumps out of the gate this morning in response to its announcement of positive results in a Phase 1 dose ranging trial assessing its antibody-drug conjugate, IMGN853 (mirvetuximab soravtansine), in patients with folate-receptor alpha-positive platinum-resistant ovarian cancer, a difficult-to-treat type with typical response rates of less than 20%.
- The overall response rate was 53% (n=9/17) which included one complete response and eight partial responses. Responses in six of the nine patients were ongoing at the time of data cutoff, with five of the six on treatment for more than 15 weeks. The data were presented as ASCO (abstract #5558).
- The company plans to initiate a Phase 2 study later this year that may support a New Drug Application (NDA) filing.
Jun. 1, 2015, 9:21 AM
Mar. 23, 2015, 12:46 PM
Mar. 23, 2015, 9:11 AM
Mar. 23, 2015, 7:47 AM
- Takeda Pharmaceutical (OTCPK:TKPHF) (OTCPK:TKPYY), through its Millennium Pharmaceuticals subsidiary, licenses exclusive rights to use ImmunoGen's (NASDAQ:IMGN) antibody-drug conjugate (ADC) technology to develop and commercialize targeted cancer therapeutics for up to two undisclosed targets, with an option for a third target for an additional upfront fee.
- Under the terms of the agreement, ImmunoGen will receive $20M upfront for each target, milestones up to $210M and royalties on net commercial sales of any resulting products.
- An antibody-drug conjugate is a cytotoxic agent attached to an antibody that binds to a target antigen found on cancer cells. This delivers the agent specifically to the cancer cells where it kills them.
- IMGN is up 23% premarket on robust volume.
Jan. 30, 2015, 12:45 PM
ImmunoGen, Inc. is a biotechnology company, which develops novel anticancer therapeutics using its antibody-drug conjugate technology. It also have developed engineered linkers that keep the payload firmly attached to the antibody while the whole therapy is circulating through the bloodstream... More
Country: United States